Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion
Sakar Healthcare Ltd 路 Investor Presentation 路 26 Oct 2026, 7:34 pm
Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion Sakar Healthcare posted robust Q2FY27 consolidated performance, with revenue rising 52% YoY to INR 8,741.61 lakhs and PAT surging 149% YoY to INR 1,130.69 lakhs. EBITDA jumped 114% YoY to INR 2,434.53 lakhs, expanding margins by 800 bps to 28%. Growth is driven by its integrated, EU-GMP-approved Bavla oncology facility, executing 69 oncology contracts with commercial supplies underway across regulated markets. The company holds 22 granted global Marketing Authorisations, 33 active tech transfers, and targets over 100 overseas contracts within two years.
Original exchange filing (PDF)
More announcements from Sakar Healthcare Ltd
- Sakar Healthcare Limited has informed the Exchange about Transcript 路 02 Nov 2026
- Sakar Healthcare Limited has informed the Exchange about Link of Recording 路 27 Oct 2026
- Sakar Healthcare Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026". 路 26 Oct 2026
- Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Schedule of meet 路 27 Oct 2026
- SAKAR HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 23 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Sakar s global export model expands with oncology products 路 14 Oct 2026
